Betagrin (batifiban) / Bio-Thera Solutions - LARVOL DELTA

Bevifibatide: First Approval. (PubMed, Drugs) - "Its first approval is as an add-on to treatment with PCI, antiplatelet and anticoagulant therapies. This article summarizes the milestones in the development of bevifibatide leading to its first approval for reducing the risk of acute occlusion, stent thrombosis, no reflow and slow blood flow in patients with ACS that requires PCI (including coronary stenting)."

Journal • Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Thrombosis

Efficacy and safety of bevifibatide in patients with acute coronary syndrome undergoing percutaneous coronary intervention (BES-PCI): A multicenter, randomized, double-blinded, placebo-controlled, phase III trial. (PubMed, Chin Med J (Engl)) - No abstract available

Clinical • Journal • P3 data • Acute Coronary Syndrome • Cardiovascular

Efficacy and Safety of Bevifibatide Citrate Injection in Patients Undergoing Endovascular Thrombectomy for Acute Ischemic Stroke: A Multi-Center, Randomized, Controlled Trial (ChiCTR) - P4 | N=154 | Not yet recruiting | Sponsor: The First Affiliated Hospital of University of South China; The First Affiliated Hospital of University of South China

New P4 trial • Cardiovascular • Ischemic stroke

Intravenous Bevifibatide in Large Vessel Occlusion Stroke Before Endovascular Thrombectomy: A Randomized, Double-blind, Placebo-controlled Trial (ESOC 2025) - "This trial is currently being prepared and will soon begin."

Clinical • Late-breaking abstract • Cardiovascular • Ischemic stroke

BCAIS-I: A Dose-Response Controlled Trial of Bevifibatide for Acute Ischemic Stroke (clinicaltrials.gov) - P2 | N=40 | Recruiting | Sponsor: Zhujiang Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • CNS Disorders • Ischemic stroke

Efficacy and Safety of Bevifibatide Citrate Injection in Patients with Acute Ischemic Stroke without Large or Medium-Sized Vessel Occlusion: A Single-Center, Randomized, Double-Blind, Dose-Response Controlled Clinical Trial (ChiCTR) - P=N/A | N=40 | Not yet recruiting | Sponsor: Zhujiang Hospital of Southern Medical University; Zhujiang Hospital of Southern Medical University

New trial • Cardiovascular • Ischemic stroke